Everything below concerns c-Met receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-03. Numbers and descriptions here follow the published literature rather than marketing material.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
== Veterinary medicine == HbA1c testing has not been found useful in the monitoring during the treatment of cats and dogs with diabetes, and is not generally used; monitoring of fructosamine levels is favoured instead.
== Applications == Mass spectrometry imaging (MSI) can be used to map the spatial distribution of biomolecules in tissue without prior labeling of specific targets. It is used in clinical pharmacological research to examine changes in proteins, lipids and metabolites associated with the disease. Applications include biomarker identification, cancer research, studies of treatment response and evaluation of drug-delivery methods. Ion colocalization has been studied as a way to infer local interactions between biomolecules. Similarly to colocalization in microscopy imaging, correlation has been used to quantify the similarity between ion images and generate network models.
== Further reading == Gollner, Adam J. (2010). The Fruit Hunters: A Story of Nature, Adventure, Commerce, and Obsession. Scribner. ISBN 978-0-7432-9695-3. Watson, R. R., and Preedy, V.R. (2010, eds.). Bioactive Foods in Promoting Health: Fruits and Vegetables. Academic Press. ISBN 978-0-12-374628-3.
==== Available forms ==== Adderall is available as immediate-release (IR) tablets and extended-release (XR) capsules. Mydayis is available as an extended-release formulation. Adderall XR is approved to treat attention deficit hyperactivity disorder for up to 12 hours in individuals 6 years and older and uses a double-bead formulation. The capsule can be swallowed like a tablet, or it can be opened and the beads sprinkled over applesauce for comparable absorption. Upon ingestion, half of the beads provide immediate administration of medication, while the other half are enveloped in a coating that must dissolve, delaying absorption of its contents. It is designed to provide a therapeutic effect and plasma concentrations identical to taking two doses of Adderall IR four hours apart. Mydayis uses a longer-lasting triple-bead formulation and is approved to treat attention deficit hyperactivity disorder for up to 16 hours in individuals aged 13 years of age and older. In the United States, the immediate and extended-release formulations of Adderall are available as generic medications. Generic formulations of Mydayis became available in the US in October 2023.
== History == The school was established by U.S. President Millard Fillmore in 1846. Buffalo was a boomtown on the Erie Canal and the gateway to the West. Leading citizens — primarily physicians and lawyers — proposed that an institution of higher learning be established, which led to the founding of the private, nonsectarian University of Buffalo. The Medical School, or Medical Department, as it was called, was the first decanal unit within the university, and 40 years passed before other departments were added. Medical classes began February 24, 1847, with an enrollment of 66 students. The medical school's first permanent location was next to Buffalo General Hospital in downtown Buffalo. In 1893, the school relocated to High Street in the city, where it remained until 1953, when it moved to the university's South Campus. It moved in 2017 to a new campus on High and Main Streets, again adjacent to the Buffalo General Hospital complex. In 1962, University of Buffalo merged with the State University of New York (SUNY) system. The Medical School then became the School of Medicine, State University of New York at Buffalo. Throughout its history, the university has not owned or operated a teaching hospital, but instead has instructed students in affiliated hospitals throughout the city. Today's network of teaching affiliations was formalized in 1983 as the Graduate Medical Dental Education Consortium of Buffalo.
Sources: en.wikipedia.org
Benzylmorphine (Peronine) is a semi-synthetic opioid narcotic introduced to the international market in 1896 and that of the United States very shortly thereafter. It is much like codeine, containing a benzyl group attached to the morphine molecule just as the methyl group creates codeine and the ethyl group creates ethylmorphine or dionine (used as a generic name for that drug just as peronine is for benzylmorphine). It is about 90% as strong as codeine by weight. This drug, the benzyl ether of morphine, should not be confused with dibenzoylmorphine, an ester of morphine comparable to heroin. Another morphine ether developed around the same time, benzyldihydromorphine, saw some clinical use in the opening years of the 20th century. The ethers of morphine and codeine as well as dihydromorphine and dihydrocodeine number close to 100 and include such obscure opioids as formylallopseudoisocodeine. Benzylmorphine is used in much the same way as codeine and ethylmorphine, primarily as a moderate strength analgesic, for eye surgery as a 1 to 2% solution, and as a cough suppressant. It was available in the United States prior to 1914 and was still used until the 1960s, but fell into disuse once alternative opiate derivatives became preferred by doctors (i.e. hydrocodone as an analgesic and codeine as a cough suppressant) Benzylmorphine is now a Schedule I Controlled Substance in the US and is regulated internationally under UN drug conventions. Benzylmorphine is an active metabolite of the opioid analgesic myrophine, formed in the liver.
=== Speed of change === VVM types are indicated by a number after "VVM". The number refers to the number of days required for the VVM to reach the discard-point (circle) color at 37 °C (99 °F). For example, VVM7 takes 7 days to turn at 37 degrees. Four main types are in use to match to the degradation rates of different vaccines: VVM30 (HepB, BCG, tetanus), VVM14 (measles, MMR), VVM7 (DPT), and VVM2 (OPV). VVM11 and VVM250 are also available. VVMs work because almost every chemical reaction corresponds to the Arrhenius equation, exponentially speeding up as the temperature increases. When time-to-change-color for a VVM or the time-to-degrade for a vaccine are plotted against the temperature on an log-linear plot, the points tend to fall in a straight line as predicted by Arrhenius (Arrhenius graph). The straight line can therefore be used to both interpolate and extrapolate the time-to-change/degrade at any given temperature. To choose the right VVM for a vaccine, one matches the known vaccine endurance data points against an Arrhenius graph of VVMs.
==== Moisture passageways ==== The driving force of moisture movement is chemical potential. However, it is not always easy to relate chemical potential in wood to commonly observable variables, such as temperature and moisture content. Moisture in wood moves within the wood as liquid or vapour through several types of passageways, based on the nature of the driving force, (e.g. pressure or moisture gradient), and variations in wood structure, as explained in the next section on driving forces for moisture movement. These pathways consist of cavities of the vessels, fibres, ray cells, pit chambers and their pit membrane openings, intercellular spaces and transitory cell wall passageways. Movement of water takes place in these passageways in any direction, longitudinally in the cells, as well as laterally from cell to cell until it reaches the lateral drying surfaces of the wood. The higher longitudinal permeability of sapwood of hardwood is generally caused by the presence of vessels. The lateral permeability and transverse flow is often very low in hardwoods. The vessels in hardwoods are sometimes blocked by the presence of tyloses and/or by secreting gums and resins in some other species, as mentioned earlier. The presence of gum veins, the formation of which is often a result of natural protective response of trees to injury, is commonly observed on the surface of sawn boards of most eucalypts.
Intending to wrest back the initiative, sever UNITA's logistics lifelines to South West Africa and Zaire, and forestall any future insurgent offensives, FAPLA launched Operation Saluting October in mid-1987. The impetus for Saluting October likely originated with the Soviet military mission, which pressed the idea of a major conventional thrust to destroy UNITA's southeastern front as early as 1983. It had received a new commander that year, Lieutenant General Pyotr Gusev, former deputy commander of the Carpathian Military District. In light of the war's length, its cost, the rising death toll, and looming cuts in the Soviet military expenditure which would limit future efforts to support FAPLA's war effort, Gusev wanted a decisive multi-divisional offensive to crush UNITA once and for all. Operation Saluting October was a two-pronged offensive aimed at retaking three major settlements from UNITA, Cangamba, Cassamba, and Mavinga. The FAPLA command staff intended the attack on Cangamba and Cassamba as a feint, hoping to draw UNITA forces there and away from Mavinga. Once Mavinga was in government hands, FAPLA could expel the remaining insurgents from Moxico Province and pave the way for a final assault on Savimbi's headquarters at Jamba. Between 4 and 9 Soviet advisers were to be attached on the battalion level, albeit with strict orders not to participate in the fighting and withdraw from the front as necessary to avoid contact with UNITA. They were accompanied by a small number of Cuban advisers and East German technical personnel serving in a variety of support roles.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.